Skip to main content
KVUE
NYSE Life Sciences

Kenvue Inc. Files Communication on Kimberly-Clark Acquisition, Details Shareholder Vote and Transaction Benefits

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Household Product Stocks · Consumer
Sentiment info
Positive
Importance info
9
Price
$17.01
Mkt Cap
$32.591B
52W Low
$14.02
52W High
$25.17
52W Position info
21% above low
Off High info
32% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

KVUE sits 21% above its 52-week low of $14.02.

Summary

Kenvue Inc. has filed a Rule 425 communication providing further details and promotional materials for its proposed acquisition by Kimberly-Clark Corporation, including the $21.01 per share consideration and upcoming shareholder vote on January 29, 2026.


Key Events · M&A and Partnerships · KVUE

  • Proposed Acquisition Details

    Kimberly-Clark Corporation is acquiring Kenvue Inc. for an enterprise value of approximately $48.7 billion, with Kenvue shareholders receiving $21.01 per share in cash and stock.

  • Shareholder Vote Scheduled

    Special meetings for both Kenvue and Kimberly-Clark stockholders are set for January 29, 2026, to approve the proposed transaction.

  • Anticipated Synergies

    The combined company expects to achieve approximately $2.1 billion in total anticipated run-rate synergies.

  • Strategic Rationale

    The merger aims to create a global health and wellness leader with highly complementary consumer offerings and a commitment to significant investment in U.S. operations.


Analysis · KVUE · Life Sciences

This filing provides crucial updates on the proposed acquisition of Kenvue by Kimberly-Clark, a significant event for Kenvue shareholders. The transaction, valued at a substantial premium to Kenvue's current market valuation, outlines a clear path to completion with a definitive shareholder vote date. The detailed financial and strategic benefits, including significant synergies and a commitment to U.S. investment, reinforce the positive outlook for the combined entity. Investors should review the definitive joint proxy statement/prospectus and participate in the upcoming vote.

At the time of this filing, KVUE was trading at $17.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32.6B. The 52-week trading range was $14.02 to $25.17. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KVUE - Latest Insights

KVUE
Jul 24, 2026, 2:03 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.16
Real-time Price: $19.71 info
Change: +$0.555 (+3%) info
Market Cap: $37.92B info
KVUE
Jul 24, 2026, 11:35 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.19
Real-time Price: $19.71 info
Change: +$0.525 (+3%) info
Market Cap: $37.92B info
KVUE
Jul 13, 2026, 10:34 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.27
Real-time Price: $19.71 info
Change: +$0.445 (+2%) info
Market Cap: $37.92B info
KVUE
May 07, 2026, 7:50 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.70
Real-time Price: $19.71 info
Change: +$2.01 (+11%) info
Market Cap: $37.92B info
KVUE
May 07, 2026, 6:35 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $17.60
Real-time Price: $19.71 info
Change: +$2.11 (+12%) info
Market Cap: $37.92B info